Avutometinib (VS-6766)

Avutometinib · Verastem, Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for Avutometinib (VS-6766), covering 2025-09-02 to 2026-04-02. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer [Phase 3]